Intellia Therapeutics Receives Innovation Passport to Treat Rare Genetic Disorder Hereditary Angioedema
January 12, 2023
Trending News ☀️
INTELLIA THERAPEUTICS ($NASDAQ:NTLA) is a leading gene editing company that uses proprietary CRISPR genome editing technology to develop therapeutic solutions for a variety of diseases. It is focused on developing treatments for liver diseases, cancer, and rare genetic disorders. On Wednesday, the company announced that it had received an Innovation Passport from the U.K.’s Medicines and Healthcare products Regulatory Agency to treat hereditary angioedema (HAE), a rare genetic disorder. HAE is a life-threatening condition caused by mutations in a protein known as C1 esterase inhibitor, or C1-INH. It has no approved treatment options, making it difficult to manage. Symptoms include severe swelling in the face and throat that can be life-threatening.
Intellia’s candidate, NTLA-2002, is an in vivo gene editing therapy designed to restore the expression of functional C1-INH protein by correcting the underlying genetic cause of HAE. The Innovation Passport is an initiative that is designed to provide patients with access to breakthrough treatments more quickly and offers a streamlined path to clinical trial approval. According to Intellia, this passport will enable them to move ahead with their clinical development program for NTLA-2002 more quickly than expected. Intellia’s innovative gene editing technology could revolutionize the way rare genetic disorders are treated in the future. With this Innovation Passport, Intellia is one step closer to bringing its cutting-edge therapy to market and providing much-needed relief to HAE patients.
Stock Price
Intellia Therapeutics, a biotechnology company that focuses on developing gene editing treatments, has recently received an Innovation Passport from the US Food and Drug Administration (FDA) to treat a rare genetic disorder called Hereditary Angioedema. This is a disorder that involves recurrent episodes of swelling, which can affect the skin, the intestines and the airways. At the time of writing, media coverage of the news was mostly positive. On Wednesday, shares of Intellia Therapeutics opened at $37.9 and closed at $37.5, down by 0.8% from the previous closing price of $37.8.
However, some analysts are optimistic about the potential of the Innovation Passport to lead to further treatments and growth for Intellia Therapeutics in the future. The Innovation Passport allows Intellia Therapeutics to develop and commercialize their gene editing treatments for Hereditary Angioedema. This could potentially provide relief to many people who suffer from this disorder and help to improve their quality of life. Furthermore, it could pave the way for Intellia Therapeutics to develop further treatments for other genetic disorders in the future. While there was a slight decrease in stock prices on Wednesday, analysts remain optimistic about the potential for growth and further treatments in the future. This could potentially provide much needed relief to people who suffer from this disorder and help to improve their quality of life. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intellia Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 51.4 | -442.02 | -844.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intellia Therapeutics. More…
| Operations | Investing | Financing |
| -298.07 | 31.35 | 79.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intellia Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.08k | 259.51 | 10.77 |
Key Ratios Snapshot
Some of the financial key ratios for Intellia Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.7% | – | -833.6% |
| FCF Margin | ROE | ROA |
| -691.4% | -31.4% | -24.7% |
VI Analysis
When it comes to assessing a company’s long-term potential, its fundamentals are key. Understanding this fact, the VI App simplifies the analysis of companies like Intellia Therapeutics. According to the VI Risk Rating, Intellia Therapeutics carries a high risk for investors in terms of financial and business aspects. The VI App has detected four risk warnings in Intellia Therapeutics’ balance sheet, cashflow statement, non-financial and financial journals. To access this information, you must be a registered user. In addition to these risk warnings, other factors to consider in evaluating Intellia Therapeutics include their financial health and ability to generate cash flows. A company’s financial health can be assessed by examining different financial metrics such as debt-to-equity ratio, return on assets and current ratio. These metrics can tell investors if the company is over or under leveraged compared to its peers. It is also important to look at the company’s liquidity position, which describes its ability to generate cash flows. This can be determined by analyzing the company’s cash flow statement and examining its operating cash flows, cash from financing activities and cash from investing activities. Overall, it is essential for investors to understand the fundamentals of a company before making any investment decisions. The VI App provides an efficient way of assessing these fundamentals and helps investors make informed decisions. More…
VI Peers
The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.
– Editas Medicine Inc ($NASDAQ:EDIT)
Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.
Summary
Intellia Therapeutics is an innovative biotechnology company that is currently developing treatments for rare genetic disorders, such as Hereditary Angioedema. The company recently received an Innovation Passport from the U.S. Food and Drug Administration, which is a positive indicator for investors. Intellia Therapeutics has a promising pipeline of treatments in development and is well-positioned to create new treatments for rare genetic disorders.
The company’s stock price has been steadily increasing due to investor optimism and the potential for new treatments to be developed. Intellia Therapeutics is an attractive investment opportunity for those looking for exposure to the biotechnology sector and the potential for strong returns on their investments.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
